Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives - Takeaways - MDSpire

Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives

  • By

  • Lingyu Jiang

  • Jiaping Wei

  • Junqi Qin

  • Jing He

  • Shengjing Liang

  • Jianwei Huang

  • Yunzhi Ma

  • Yifan Zhou

  • Yonglong Zhong

  • June 10, 2026

  • 0 min

Share

  • 1

    Efgartigimod is a first-in-class FcRn antagonist that has significantly improved treatment outcomes for generalized myasthenia gravis (gMG).

  • 2

    The phase 3 ADAPT trial showed that 68% of AChR-Ab+ patients treated with efgartigimod achieved clinically meaningful improvements in MG-ADL scores.

  • 3

    Long-term studies confirmed efgartigimod's efficacy and safety, with consistent improvements across multiple treatment cycles and a favorable safety profile.

  • 4

    Real-world evidence supports efgartigimod's effectiveness in diverse patient populations, including those with acute exacerbations and thymoma-associated MG.

  • 5

    Ongoing research is focused on optimizing patient selection, exploring combination therapies, and expanding efgartigimod's applications to other autoimmune diseases.

Original Source(s)

Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives

  • by Lingyu Jiang, Jiaping Wei, Junqi Qin, Jing He, Shengjing Liang, Jianwei Huang, Yunzhi Ma, Yifan Zhou, Yonglong Zhong

  • June 10, 2026

Related Content

Virtual reality training for gait disorders in Parkinson’s disease: a bibliometric and visual analysis of hotspots and trends using CiteSpace and VOSviewer

An interpretable TimeMIL framework for fNIRS: differential diagnosis between schizophrenia and bipolar disorder

Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis